

Curriculum Vitae

Thomas Thum Professor, Dr. Dr. med.
d.o.b. November 16th, 1974, in Hildesheim, Germany

University Education

2009 Habilitation, Hannover Medical School (MHH)
2009/10 Board Examination Internal Medicine / Cardiology
2002-2008 Ph.D. at Imperial College London, UK
2001 Doctorate Medicine, MHH
1994-2001 Studies of Medicine, MHH

Scientific Career

2021-2023 Director Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover
Since 2020 Member Life Science Startup Board of Lower Saxony
Since 2018 Spokesperson 'Research Center for Translational Regenerative Medicine' (previously REBIRTH Cluster of Excellence)
2009-2018 Section Leader, Integrated Research and Treatment Center Transplantation (IFB-Tx), MHH
Since 2013 Visiting Professor, National Heart and Lung Institute, Imperial College London, U.K.
Since 2009 Full Professor (W3) and Director of the Institute of Molecular and Translational Therapeutic Strategies, MHH
2006-2009 Research Junior Group Leader 'Cardiac Wounding and Healing', Interdisciplinary Center for Clinical Research, Julius-Maximilians-University, Würzburg
2004-2009 Department of Internal Medicine I, Julius-Maximilians-University Würzburg
2003-2004 Postdoctoral Fellow, Department of Clinical Pharmacology, MHH and Fraunhofer Institute for Experimental Medicine
2001-2002 Postdoctoral Fellow, Department of Clinical Pharmacology, MHH

Awards and Honors (selection)

2022 Desmond-Julian Award, ESC
2022 ERC Advanced Grant "REVERSE"
2021 Paul-Martini-Award, Paul Martini Foundation, Berlin, Germany
2020 ERC Proof of concept Grant "MEGFIB"
2015 Outstanding Investigator Award, ISHR, Bordeaux, France
2015 ERC Consolidator Grant "LONGHEART"
2014 Sir Hans Krebs Award, Hannover Medical School, Germany
2012 Franz-Maximilian-Groedel Award, German Society of Cardiology
2011 Outstanding Achievement Award, European Society of Cardiology
2010 Albert-Fraenkel-Award, German Society of Cardiology
2009 German Pfizer Research Award for Medicine, Freiburg
2008 Young Investigator Award, European Heart Failure Meeting, Milano, Italy
2006 William W. Parmley Young Author Achievement Award, ACC, Atlanta, USA
2005 Young Investigator Award, European Society of Cardiology, Stockholm, Sweden
2005 Parmley-Award, American College of Cardiology
2001 Hugo-Geiger-Award, Bavarian Ministry of Science, Germany

Citation Record

Total citations: 58.620; h-index:114; h-index since 2019: 81 (Google Scholar July 19th, 2024)

Top-10 selected Publications

Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C, Levin AA, Bauersachs J, Solomon SD, **Thum T**. Novel antisense therapy targeting microRNA-132 in

patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. **Eur Heart J**; 2021;42:178–188. doi: [10.1093/eurheartj/ehaa898](https://doi.org/10.1093/eurheartj/ehaa898)

Foinquinos A, Batkai S, Genschel C, Viereck J, Rump S, Gyongyosi M, Traxler D, Riesenhuber M, Spannauer A, Lukovic D, Weber N, Zlabinger K, Hasimbegovic E, Winkler J, Fiedler J, Dangwal S, Fischer M, la Roche J de, Wojciechowski D, Kraft T, Garamvolgyi R, Neitzel S, Chatterjee S, Yin X, Bar C, Mayr M, Xiao K, **Thum T**. Preclinical development of a miR-132 inhibitor for heart failure treatment. **Nat Commun**; 2020;11:633. doi: [10.1038/s41467-020-14349-2](https://doi.org/10.1038/s41467-020-14349-2)

Viereck J, Bürke A, Foinquinos A, Chatterjee S, Kleeberger JA, Xiao K, Janssen-Peters H, Batkai S, Ramanujam D, Kraft T, Cebotari S, Gueler F, Beyer AM, Schmitz J, Bräsen JH, Schmitto JD, Gyöngyösi M, Löser A, Hirt MN, Eschenhagen T, Engelhardt S, Bär C, **Thum T**. Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. **Eur Heart J**; 2020;41:3462–3474. doi: [10.1093/eurheartj/ehaa519](https://doi.org/10.1093/eurheartj/ehaa519)

Schimmel K, Jung M, Foinquinos A, José GS, Beaumont J, Bock K, Grote-Levi L, Xiao K, Bär C, Pfanne A, Just A, Zimmer K, Ngoy S, López B, Ravassa S, Samolovac S, Janssen-Peters H, Remke J, Scherf K, Dangwal S, Piccoli MT, Kleemiss F, Kreutzer FP, Kenneweg F, Leonardy J, Hobuß L, Santer L, Do QT, Geffers R, Braesen JH, et al. **Thum T**. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. **Circulation**; 2020;141:751–767. doi: [10.1161/CIRCULATIONAHA.119.042559](https://doi.org/10.1161/CIRCULATIONAHA.119.042559)

Kreutzer FP, Meinecke A, Mitzka S, Hunkler HJ, Hobuß L, Abbas N, Geffers R, Weusthoff J, Xiao K, Jonigk DD, Fiedler J, **Thum T**. Development and characterization of anti-fibrotic natural compound similars with improved effectivity. **Basic Res Cardiol**; 2022;117:9. doi: [10.1007/s00395-022-00919-6](https://doi.org/10.1007/s00395-022-00919-6)

Piccoli M-T, Gupta SK, Viereck J, Foinquinos A, Samolovac S, Kramer FL, Garg A, Remke J, Zimmer K, Batkai S, **Thum T**. Inhibition of the Cardiac Fibroblast-Enriched lncRNA Meg3 Prevents Cardiac Fibrosis and Diastolic Dysfunction. **Circ Res**; 2017;121:575–583. doi: [10.1161/CIRCRESAHA.117.310624](https://doi.org/10.1161/CIRCRESAHA.117.310624)

Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, Windt LJ de, Engelhardt S, Dandekar T, Batkai S, **Thum T**. Long noncoding RNA Chast promotes cardiac remodeling. **Sci Transl Med**; 2016;8:326ra22. doi: [10.1126/scitranslmed.aaf1475](https://doi.org/10.1126/scitranslmed.aaf1475)

Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, Dangwal S, Kumarswamy R, Bang C, Holzmann A, Remke J, Caprio M, Jentzsch C, Engelhardt S, Geisendorf S, Glas C, Hofmann TG, Nessling M, Richter K, Schiffer M, Carrier L, Napp LC, Bauersachs J, Chowdhury K, **Thum T**. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. **Nat Commun**; 2012;3:1078. doi: [10.1038/ncomms2090](https://doi.org/10.1038/ncomms2090)

Ucar A, Vafaizadeh V, Jarry H, Fiedler J, Klemmt PAB, **Thum T**, Groner B, Chowdhury K. miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. **Nat Genet**; 2010;42:1101–1108. doi: [10.1038/ng.709](https://doi.org/10.1038/ng.709)

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliensky V, Rosenwald A, Basson MA, Licht JD, Pena JTR, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. **Nature**; 2008; 456:980–984. doi: [10.1038/nature07511](https://doi.org/10.1038/nature07511)